2-Apr-2024	Optiscan appoints US Clinical & Regulatory Heads

20-Mar-2024	Optiscan receives R&D Tax Incentive Rebate

23-Feb-2024	OIL Appendix 4D and 31 December 2023 Half-year report

13-Feb-2024	Optiscan receives $3 million CRC-P Industry Grant

31-Jan-2024	OIL December 2023 Quarterly Report and Appendix 4C

23-Nov-2023	Change of Company Auditor

23-Nov-2023	Results of Annual General Meeting

23-Nov-2023	OIL Managing Director's Presentation & Chair's Address

14-Nov-2023	Response to ASX Price Query

2-Nov-2023	Section 708A Cleansing Notice

2-Nov-2023	Application for quotation of securities - OIL

31-Oct-2023	OIL September 2023 Quarterly Report and Appendix 4C

24-Oct-2023	Notice of Annual General Meeting/Proxy Form

24-Oct-2023	2023 AGM - Letter to Shareholders & Proxy Form

23-Oct-2023	Optiscan Announces Chief Operating Officer Appointment

10-Oct-2023	Optiscan announces key appointments for US operation

5-Oct-2023	Annual General Meeting Date

19-Sep-2023	Optiscan Correlates with Histology in Breast Study

31-Aug-2023	Appendix 4G & Corporate Governance Statement

31-Aug-2023	OIL Appendix 4E and June 2023 Annual Report

15-Aug-2023	Optiscan Achieves Telepathology Milestone

2-Aug-2023	Change in substantial holding

1-Aug-2023	Change in substantial holding

31-Jul-2023	Application for quotation of securities - OIL

28-Jul-2023	Change of Director's Interest Notice

28-Jul-2023	OIL June 2023 Quarterly Report and Appendix 4C

20-Jul-2023	Change in substantial holding

19-Jul-2023	Change in substantial holding

18-Jul-2023	Change of Director's Interest Notices x3

13-Jul-2023	Application for quotation of securities - OIL

13-Jul-2023	Notification of cessation of securities - OIL

12-Jul-2023	Entitlement Offer Results and Shortfall Announcement

10-Jul-2023	Optiscan to present at key international congress in July

26-Jun-2023	Update - Proposed issue of securities - OIL

26-Jun-2023	Entitlement Offer Extension to Closing Date

7-Jun-2023	Entitlement Offer - Letter to Ineligible Shareholders

7-Jun-2023	Entitlement Offer documents despatched to Shareholders

30-May-2023	Entitlement Offer Timetable Update

30-May-2023	Proposed issue of securities - OIL

30-May-2023	Optiscan Entitlement Issue Prospectus

30-May-2023	Optiscan Launches Entitlement Offer to Raise $16.7M

26-May-2023	Trading Halt

15-May-2023	Optiscan Oral Study Published in Prestigious Medical Journal

28-Apr-2023	OIL March 2023 Quarterly Report and Appendix 4C

21-Apr-2023	Change of Director's Interest Notice

21-Apr-2023	Notification of cessation of securities - OIL

3-Apr-2023	Optiscan Establishes US Commercial Operation in Minnesota

31-Mar-2023	Change of Director's Interest Notice - K Borg

30-Mar-2023	Change of Director's Interest Notice - R Cooke

14-Mar-2023	Optiscan Platform Highly Accurate for Oral Cancer Diagnosis

2-Mar-2023	Optiscan Intends to pursue De Novo Pathway for InVivage

27-Feb-2023	OIL Appendix 4D and 31 December 2022 Half-year report

30-Jan-2023	Optiscan partners with Prolucid to develop AI Algorithms

27-Jan-2023	OIL December 2022 Quarterly Report and Appendix 4C

11-Jan-2023	Section 708A Cleansing Notice

11-Jan-2023	Application for quotation of securities - OIL

8-Dec-2022	Section 708A Cleansing Notice

8-Dec-2022	Application for quotation of securities - OIL

24-Nov-2022	Results of Annual General Meeting

24-Nov-2022	Optiscan Managing Director 2022 AGM Presentation

24-Nov-2022	Optiscan Chairman's AGM Address

4-Nov-2022	Statement pursuant to Listing Rule 4.7C.3

31-Oct-2022	OIL September 2022 Quarterly Report and Appendix 4C

25-Oct-2022	2022 AGM - Letter to Shareholders & Proxy Form

25-Oct-2022	Notice of Annual General Meeting/Proxy Form

25-Oct-2022	Proposed issue of securities - OIL

25-Oct-2022	Optiscan Imaging Acquires Intellectual Property

24-Oct-2022	Optiscan receives R&D tax incentive rebate

6-Oct-2022	Annual General Meeting Date

31-Aug-2022	Appendix 4G & Corporate Governance Statement

31-Aug-2022	Appendix 4E and 2022 Annual Report

22-Aug-2022	Optiscan Submits FDA 510(k) Application for InVivage Device

29-Jul-2022	OIL June 2022 Quarterly Report and Appendix 4C

28-Jul-2022	Change in substantial holding

14-Jul-2022	Notification of cessation of securities - OIL

1-Jul-2022	Section 708A Cleansing Notice

1-Jul-2022	Application for quotation of securities - OIL

28-Jun-2022	Strategic Distribution Partnership - Additional Information

27-Jun-2022	Optiscan announces Strategic Distribution Partner for China

20-Jun-2022	Optiscan to present at Head & Neck Cancer World Congress

17-Jun-2022	Initial Director's Interest Notice

14-Jun-2022	Appointment of Non-executive Director

1-Jun-2022	Section 708A Cleansing Notice

1-Jun-2022	Application for quotation of securities - OIL

29-Apr-2022	OIL March 2022 Quarterly Report and Appendix 4C

26-Apr-2022	Optiscan appoints key management staff

13-Apr-2022	Change in substantial holding

17-Mar-2022	Change in substantial holding

10-Mar-2022	Change of Director's Interest Notice

10-Mar-2022	Notification regarding unquoted securities - OIL

10-Mar-2022	Notification regarding unquoted securities - OIL

24-Feb-2022	Appendix 4D and 31 December 2021 Half-year report

31-Jan-2022	OIL December 2021 Quarterly Report and Appendix 4C

20-Jan-2022	Results of Annual General Meeting

20-Jan-2022	Final Director's Interest Notice

20-Jan-2022	2021 AGM Chairman's Address and MD Presentation

20-Dec-2021	Notice of Annual General Meeting/Proxy Form

20-Dec-2021	2021 AGM Letter to Shareholders and Proxy Form

15-Dec-2021	Section 708A Cleansing Notice

15-Dec-2021	Application for quotation of securities - OIL

13-Dec-2021	Final Director's Interest Notice

13-Dec-2021	Change of Managing Director

12-Nov-2021	Completion of imaging for Melbourne Breast cancer trial

10-Nov-2021	Jobkeeper Payments Notice

2-Nov-2021	Update to Annual General Meeting Date

27-Oct-2021	OIL September 2021 Quarterly Report and Appendix 4C

25-Oct-2021	Receipt of R&D Tax Incentive Rebate

4-Oct-2021	Annual General Meeting Date

15-Sep-2021	Section 708A Cleansing Notice

15-Sep-2021	Application for quotation of securities - OIL

15-Sep-2021	Application for quotation of securities - OIL

15-Sep-2021	Application for quotation of securities - OIL

30-Aug-2021	Appendix 4G and Corporate Governance Statement

30-Aug-2021	OIL FY21 Annual Results Presentation

30-Aug-2021	Appendix 4E and 2021 Annual Report

9-Aug-2021	Change of Director's Interest Notice

9-Aug-2021	Notification regarding unquoted securities - OIL

9-Aug-2021	Section 708A Cleansing Notice

9-Aug-2021	Application for quotation of securities - OIL

30-Jul-2021	Final Director's Interest Notice

30-Jul-2021	OIL June 2021 Quarterly Report and Appendix 4C

29-Jul-2021	Initial Director's Interest Notice

29-Jul-2021	Proposed issue of securities - OIL

29-Jul-2021	Appointment and Resignation of Independent Director

16-Jul-2021	Section 708A Cleansing Notice

16-Jul-2021	Application for quotation of securities - OIL

30-Jun-2021	Section 708A Cleansing Notice

30-Jun-2021	Application for quotation of securities - OIL

1-Jun-2021	Section 708A Cleansing Notice and Appendix 2A

1-Jun-2021	Update on seeking United States FDA approval & market entry

10-May-2021	Change in substantial holding

6-May-2021	Section 708A Cleansing Notice and Appendix 2A

6-May-2021	Change of Director's Interest Notice

6-May-2021	Appendix 3G

6-May-2021	Appointment of new Non-executive Director

29-Apr-2021	OIL March 2021 Quarterly Report and Appendix 4C

19-Apr-2021	Initial Director's Interest Notice

19-Apr-2021	Appointment of New Non-executive Chair

1-Apr-2021	Change of Director's Interest Notices x2

1-Apr-2021	Exercise of options by Directors & Appendix 2A

24-Mar-2021	Section 708A Cleansing Notice and Appendix 2A

11-Mar-2021	Section 708A Cleansing Notice and Appendix 2A

25-Feb-2021	Appendix 4D and Financial Statements - 31 December 2020

10-Feb-2021	Appointment of new Non-executive Director

8-Feb-2021	OIL breast cancer study to commence next stage - revised

8-Feb-2021	Optiscan breast cancer study to commence next stage

1-Feb-2021	Section 708A Cleansing Notice and Appendix 2A

29-Jan-2021	OIL December 2020 Quarterly Report and Appendix 4C

13-Jan-2021	Carl Zeiss Meditec AG Product Orders

16-Dec-2020	Appointment of Taiwan Distributor

9-Dec-2020	Appendix 3G - issue of options

9-Dec-2020	Appendix 3G - issue of options

26-Nov-2020	Results of Annual General Meeting

26-Nov-2020	OIL 2020 AGM Presentation

25-Nov-2020	Annual General Meeting Resolution Withdrawal

10-Nov-2020	TGA Approval for CONVIVO and Sterile Sheath In Australia

30-Oct-2020	OIL September 2020 Quarterly Report and Appendix 4C

29-Oct-2020	Presentation at Australia Biotech Invest & Partnering 2020

27-Oct-2020	Notice of Annual General Meeting/Proxy Form

27-Oct-2020	2020 AGM Letter to Shareholders and Proxy Form

9-Oct-2020	US FDA Regulatory Approval update

2-Oct-2020	Change in substantial holding

2-Oct-2020	Becoming a substantial holder

1-Oct-2020	Section 708A Cleansing Notice and Appendix 2A

1-Oct-2020	Annual General Meeting Date

29-Sep-2020	Section 708A Cleansing Notice and Appendix 2A

25-Sep-2020	Receipt of R&D Tax Incentive Rebate

25-Sep-2020	OptiScan Capital Raising

22-Sep-2020	Proposed issue of Securities - OIL

22-Sep-2020	Optiscan Capital Raising

21-Sep-2020	Trading Halt

21-Sep-2020	Pause in Trading

8-Sep-2020	Response to ASX Price Query

31-Aug-2020	Appendix 4G and Corporate Governance Statement

31-Aug-2020	Appendix 4E and 2020 Annual Report

28-Aug-2020	New North American & Expanded Asia Pacific Distribution

25-Aug-2020	Optiscan Investor Presentation

31-Jul-2020	OIL June 2020 Quarterly Report and Appendix 4C

28-Jul-2020	2 X China Tender Success for FIVE2 (ViewnVivo)

24-Jul-2020	Optiscan Presentation

20-Jul-2020	Government grant to support Melbourne Dental School Trial

3-Jul-2020	Optiscan Presentation

4-May-2020	Achievement of Final Milestone in Carl Zeiss Agreement

30-Apr-2020	Amended Securities Trading Policy

30-Apr-2020	OIL March 2020 Quarterly Report and Appendix 4C

7-Apr-2020	Response to ASX Price Query

7-Apr-2020	Pause in Trading

20-Mar-2020	Corporate Update

28-Feb-2020	Appendix 4D and Financial Statements - 31 December 2019

28-Feb-2020	OIL Wholesale Investor Presentation - February 2020

31-Jan-2020	Corporate Update - January 2020

12-Dec-2019	Change of Director's Interest Notices x3

12-Dec-2019	Section 708A Notice and Appendix 3B

5-Dec-2019	Appointment of Second China Distributor

28-Nov-2019	Results of Annual General Meeting

28-Nov-2019	2019 AGM Presentation

25-Nov-2019	Optiscan Market Update

19-Nov-2019	Optiscan to Hold Investor Presentation in Perth

4-Nov-2019	OIL initiates FDA feedback for Oral Cancer 510(k) submission

31-Oct-2019	Optiscan Presentation at AusBiotech Conference

25-Oct-2019	Notice of Annual General Meeting/Proxy Form

16-Oct-2019	Appointment of new China Distributor

3-Oct-2019	Receipt of R&D Tax Incentive Rebate

23-Sep-2019	Leading Aus & US Hospital Collaboration to trial OIL device

16-Sep-2019	Change of Director's Interest Notice - G Mutton

10-Sep-2019	Presentation at World Federation for Utrasound Conference

30-Aug-2019	Appendix 4G and Corporate Governance Statement

30-Aug-2019	Appendix 4E and 2019 Annual Report

29-Aug-2019	Amended Securities Trading Policy

21-Aug-2019	Optiscan System Approved for Prestigious Cancer Centre Trial

20-Jun-2019	Section 708A Notice and Appendix 3B

14-Jun-2019	Investor Presentation - June 2019

14-Jun-2019	Optiscan Secures Strong Support in $1.70 M Capital Raising

12-Jun-2019	Trading Halt

6-May-2019	Change of Director's Interest Notice

6-May-2019	Change of Director's Interest Notice

29-Apr-2019	Investor Presentation - April 2019

14-Mar-2019	OptiScan March 2019 Presentation (Amended)

14-Mar-2019	OptiScan March 2019 Presentation

28-Feb-2019	Appendix 4D and Financial Statements - 31 Dec 2018

26-Feb-2019	Collaboration Agreement with Summit Biomedical Imaging LLC

26-Feb-2019	OptiScan technology used in research at major cancer centre

21-Dec-2018	Change of Director's Interest Notices x3

21-Dec-2018	Appendix 3B

30-Nov-2018	Results of Annual General Meeting

30-Nov-2018	AGM Presentation

21-Nov-2018	Optiscan to Hold Investor Presentation in Perth

16-Nov-2018	Management Update

8-Nov-2018	Receipt of R&D Tax Incentive Rebate

7-Nov-2018	Reinstatement to Official Quotation

7-Nov-2018	ZEISS achieves another milestone on regulatory pathway

2-Nov-2018	Suspension from Official Quotation

31-Oct-2018	Trading Halt Request

31-Oct-2018	Trading Halt

30-Oct-2018	Notice of Annual General Meeting/Proxy Form

15-Oct-2018	Clinical Trial - Assessment of Breast Cancer Margin

31-Aug-2018	Appendix 4G and Corporate Governance Statement

31-Aug-2018	Appendix 4E and 2018 Annual Report

28-Jun-2018	Appendix 3B

26-Jun-2018	Receipt of R&D Tax Incentive Rebate

13-Jun-2018	Market Update

7-Jun-2018	Appendix 3B

31-May-2018	ZEISS CONVIVO and Appointment of Interim Executive Chairman

18-May-2018	Change of Director's Interest Notice - Graeme Mutton

18-May-2018	Ceasing to be a substantial holder

11-May-2018	Final Director's Interest Notice

10-May-2018	Results of General Meeting

9-May-2018	Appointment of Chairman & General Meeting Update

27-Apr-2018	Initial Director's Interest Notice - Graeme Mutton

27-Apr-2018	Initial Director's Interest Notice - Darren Lurie

27-Apr-2018	Final Director's Interest Notice - Ian Griffiths

27-Apr-2018	Final Director's Interest Notice - Peter Francis

26-Apr-2018	Withdrawal of Senior Management Team Resignations

23-Apr-2018	Final Director's Interest Notice - Alan Hoffman

23-Apr-2018	Resignation and Appointment of Non-Executive Directors

18-Apr-2018	Resignation of Director

16-Apr-2018	Successful European conference participation

4-Apr-2018	Notice of General Meeting/Proxy Form

3-Apr-2018	Q&A with Executive Chairman - Alan Hoffman

27-Mar-2018	Shareholder requisitions and forthcoming management changes

26-Mar-2018	Notice of initial substantial shareholder

26-Mar-2018	Receipt of Shareholder requisition notice

16-Mar-2018	Notice of initial substantial shareholder

15-Mar-2018	Receipt of Shareholder requisition notice

1-Mar-2018	Optiscan Mid-Year Results

28-Feb-2018	Appendix 4D and Financial Statements - 31 Dec 2017

16-Feb-2018	Update on CEO Recruitment and Interim Management

29-Jan-2018	Appendix 3B

22-Jan-2018	Market Update - Resignation of CEO

22-Dec-2017	Market Update

30-Nov-2017	Amended Constitution

24-Nov-2017	Appendix 3B

24-Nov-2017	Results of Annual General Meeting

24-Nov-2017	CEO AGM Presentation

24-Nov-2017	Chairman's AGM Address

17-Nov-2017	ViewnVivo installed for evaluation at Stanford University

13-Nov-2017	First Sales of ViewnVivo in the Chinese Market

7-Nov-2017	WA Investor Presentation - November 2017

31-Oct-2017	Appendix 3Y - Peter Francis

31-Oct-2017	Corrected Appendix 3Y

30-Oct-2017	Appendix 3Y - Ian Griffiths

27-Oct-2017	Appendix 3Y - Philip Currie

27-Oct-2017	Appendix 3Y - Ian Mann

24-Oct-2017	Appendix 3B

24-Oct-2017	Notice of Annual General Meeting/Proxy Form

24-Oct-2017	2017 Annual Report to Shareholders

19-Oct-2017	Market Update on Convivo

18-Oct-2017	Appendix 3B

10-Oct-2017	Change in substantial holding

10-Oct-2017	Change of Director's Interest Notices x3

10-Oct-2017	Zeiss/Optiscan collaboration unveils Convivo

6-Oct-2017	Change in substantial holding

4-Oct-2017	Section 708A Cleansing Statement & Appendix 3B

4-Oct-2017	Share Purchase Plan and Placement Completion

28-Sep-2017	Appendix 4G and Corporate Governance Statement

28-Sep-2017	2017 Annual Report to Shareholders

27-Sep-2017	Investor Presentation - September 2017

26-Sep-2017	Share Purchase Plan Results

21-Sep-2017	Carl Zeiss Meditec to unveil in vivo Digital Biopsy Tool

14-Sep-2017	Optiscan Appoints Exclusive China Distributor

12-Sep-2017	An update from the Chairman

29-Aug-2017	Despatch of Share Purchase Plan Documents to Shareholders

29-Aug-2017	Notice under ASIC Class Order 09/425 - Share Purchase Plan

29-Aug-2017	Preliminary Final Report - Appendix 4E

23-Aug-2017	Share Placement and Underwritten Share Purchase Plan

21-Aug-2017	Trading Halt

16-Aug-2017	ViewnVivo Update

10-Aug-2017	Appendix 3B

20-Jul-2017	Market Update

17-Jul-2017	Initial Director's Interest Notice

17-Jul-2017	Director Appointment

3-Jul-2017	Investor Presentation - July 2017

28-Jun-2017	Optiscan Appoints Exclusive North American Distributor

6-Jun-2017	Market Update

16-May-2017	Change of Registered Office and Principal Place of Business

28-Apr-2017	Market Update

31-Mar-2017	Market Update

15-Mar-2017	Change of Director's Interest Notice

15-Mar-2017	Appendix 3B

8-Mar-2017	Amended Appendix 4D

2-Mar-2017	Market Update

28-Feb-2017	Appendix 4D and Financial Statements - 31 Dec 2016

30-Dec-2016	Resignation of Joint Company Secretary

29-Dec-2016	Becoming a substantial holder

29-Dec-2016	Amended Share Trading Policy

28-Dec-2016	Change in substantial holding

28-Dec-2016	Share Placement Completion and Appendix 3B

28-Dec-2016	Cleansing Prospectus

23-Dec-2016	Market Update - December 2016

22-Dec-2016	Change of Director's Interest Notices (x4)

22-Dec-2016	Appendix 3B

21-Dec-2016	Prospectus - Share and Option Issues approved at AGM

21-Dec-2016	Share Placement

19-Dec-2016	Trading Halt

16-Dec-2016	Company Secretary Appointment/Resignation

25-Nov-2016	AGM voting- results

25-Nov-2016	AGM- other than Chairman's address

25-Nov-2016	AGM- Chairman's address

22-Nov-2016	Pre-clinical research product launch

8-Nov-2016	Receipt of R&D tax rebate incentive

7-Nov-2016	Optiscan to hold investor presentation in Perth- Wed 30 Nov

26-Oct-2016	AGM Notice of Meeting and Proxy Form

19-Oct-2016	Response to ASX Price Query

14-Oct-2016	Change of interests of substantial shareholder- form 604

28-Sep-2016	Appendix 4G and Corporate Governance Statement

28-Sep-2016	Annual Report

8-Sep-2016	Optiscan Completes $2.16M Capital Raising

8-Sep-2016	Completion of rights issue - shares issued

31-Aug-2016	Preliminary Final Report- Appendix 4E

24-Aug-2016	Appendix 3Y- increase in Director's interest

22-Aug-2016	Update on cooperation with Carl Zeiss Meditec

19-Aug-2016	Reinstatement to Official Quotation - 22 August 2016

19-Aug-2016	Shares issued 19 August 2016 and request for reinstatement

19-Aug-2016	Appendix 3B- shares issued 19 August 2016

17-Aug-2016	Optiscan rights issue- shortfall notice

5-Aug-2016	Rights issue- Confirmation of lodgement of documents

3-Aug-2016	Optiscan announces new General Manager appointment

29-Jul-2016	Rights issue- supplementary prospectus

27-Jul-2016	Rights issue- letter to ineligible shareholders

27-Jul-2016	Rights issue- letter to eligible shareholders

26-Jul-2016	Rights issue- updated Appendix 3B

25-Jul-2016	Rights issue- letter sent to option-holders

25-Jul-2016	Chairman's letter- rights issue

25-Jul-2016	2 for 9 rights issue - prospectus

22-Jul-2016	Conversion of Director Loan to Equity

8-Jul-2016	2 for 9 rights issue- notification of revised timing

6-Jul-2016	New issue announcement

28-Jun-2016	Announcement- capital raising

28-Jun-2016	2 for 9 rights issue- appendix 3B

10-Jun-2016	Change of Company Secretary and CFO

30-May-2016	Update - Mid Year Accounts and Capital Raise

30-May-2016	Optiscan Appendix 4D and Financial Statements (31 Dec 2015)

17-May-2016	Update - 31 Dec 2015 Interim Report

13-May-2016	CEO Appointment

4-May-2016	Initial Director's Interest Notice

3-May-2016	Final Director's Interest Notice

3-May-2016	Initial Director's Interest Notice

3-May-2016	Initial Director's Interest Notice

3-May-2016	Board Changes

29-Apr-2016	Funding Update and Ongoing Suspension

13-Apr-2016	Final Director's Interest Notice

13-Apr-2016	Director Appointment/Resignation

31-Mar-2016	Optiscan Suspension and Funding Update

29-Feb-2016	Optiscan Funding and Suspension Update

24-Feb-2016	Suspension from Official Quotation

22-Feb-2016	Trading Halt

11-Jan-2016	Optiscan Receives R&D Tax Incentive, Loan Repaid

5-Jan-2016	Appendix 3B

9-Dec-2015	Final Director's Interest Notice

9-Dec-2015	Board Changes and Funding Update

9-Dec-2015	Initial Director's Interest Notice

30-Nov-2015	Results of Meeting

30-Nov-2015	Chairman's Address to Shareholders

17-Nov-2015	CellLIVE Update

30-Oct-2015	Notice of Annual General Meeting/Proxy Form

14-Oct-2015	Optiscan Corporate Governance Policy Statement 2015

30-Sep-2015	Optiscan Appendix 4G

30-Sep-2015	Full Year Statutory Accounts

25-Sep-2015	Reinstatement to Official Quotation

25-Sep-2015	Optiscan Zeiss Collaboration Update

23-Sep-2015	Suspension from Official Quotation

21-Sep-2015	Trading Halt

16-Sep-2015	Final Director's Interest Notice

16-Sep-2015	Board of Directors Change

3-Sep-2015	Global Launch of CellLIVe in Hawaii, USA

28-Aug-2015	Optiscan Appendix 4E and Financial Statements

22-Jul-2015	Entitlements Issue Completed

21-Jul-2015	Initial Director's Interest Notice

21-Jul-2015	Initial Director's Interest Notice

21-Jul-2015	Final Director's Interest Notice

21-Jul-2015	Letter to Shareholders from Angus Holt

21-Jul-2015	Board Changes at Optiscan

20-Jul-2015	Trading Halt

16-Jul-2015	Change of Director's Interest Notice

16-Jul-2015	Change of Director's Interest Notice

16-Jul-2015	Change of Director's Interest Notice

10-Jul-2015	Response to ASX Query

9-Jul-2015	Notice of Shortfall for Entitlements Issue

3-Jul-2015	Change of Directors Interest

3-Jul-2015	Appendix to Form 604

3-Jul-2015	Change in Substantial

3-Jul-2015	Change of Interests Cover Letter

15-Jun-2015	Reinstatement to Official Quotation

15-Jun-2015	Notice under s708A

15-Jun-2015	Appendix 3B

15-Jun-2015	Non-Renounceable Issue

15-Jun-2015	Funding and Update

10-Jun-2015	Suspension From Official Quotation

5-Jun-2015	Trading Halt

27-Feb-2015	Half Yearly Report and Accounts

11-Feb-2015	Response to ASX Price Query

14-Jan-2015	Response to ASX Price Query

13-Jan-2015	Appendix 3B

12-Dec-2014	Change of Director's Interest Notice

12-Dec-2014	Change of Director's Interest Notice

12-Dec-2014	Change of Director's Interest Notice

11-Dec-2014	Appendix 3B

5-Dec-2014	Appendix 3B

26-Nov-2014	Appendix 3B

25-Nov-2014	Results of Meeting

25-Nov-2014	Chairman's Address to Shareholders

17-Nov-2014	Notice under S708A

17-Nov-2014	Appendix 3B

14-Nov-2014	Major Milestone Recognised

24-Oct-2014	Notice of Annual General Meeting/Proxy Form

30-Sep-2014	Full Year Statutory Accounts

29-Sep-2014	Market Introduction of CellLIVE by MR Solutions and Optiscan

23-Sep-2014	Change in substantial holding

23-Sep-2014	S708A Notice

23-Sep-2014	Appendix 3B

23-Sep-2014	NEW FUNDING FOR OPTISCAN

22-Sep-2014	Trading Halt

29-Aug-2014	Preliminary Final Report

27-Aug-2014	Major Step in Zeiss Product Development

21-Jul-2014	Section 708A Notice

21-Jul-2014	Appendix 3B

15-Jul-2014	New Funding Facility and Operations Update

14-Jul-2014	Trading Halt

11-Jun-2014	S708A Notice

11-Jun-2014	Appendix 3B

29-Apr-2014	S708A Notice

29-Apr-2014	Appendix 3B

3-Mar-2014	Optiscan in Clinical Study at St Vincents Sydney

28-Feb-2014	Notice under S708A

28-Feb-2014	Appendix 3B

28-Feb-2014	Half Yearly Report and Accounts

21-Feb-2014	Publications Support Optiscan's New Product Directions

19-Feb-2014	Change of Director's Interest Notice

18-Feb-2014	New Global Supply Agreement

23-Jan-2014	Appendix 3B Amended

22-Jan-2014	Appendix 3B

15-Jan-2014	Response to ASX Query

12-Dec-2013	Appendix 3B

5-Dec-2013	Appendix 3Y Angus Holt

26-Nov-2013	Notice Under S708A

26-Nov-2013	Appendix 3B

19-Nov-2013	AGM Results

19-Nov-2013	Chairman's Address to Shareholders

1-Nov-2013	Notice under S708A

1-Nov-2013	Appendix 3B

15-Oct-2013	Notice under S 708A

15-Oct-2013	Notice of Annual General Meeting/Proxy Form

8-Oct-2013	Change in substantial holding from CIR

7-Oct-2013	Change of Director's Interest Notice

7-Oct-2013	Appendix 3B with Appendix

7-Oct-2013	Appendix 3B

30-Sep-2013	Annual Report to shareholders

30-Aug-2013	Notice under Section 708A(5)(e) Corporations Act

30-Aug-2013	Appendix 3B

30-Aug-2013	Appendix 3B

30-Aug-2013	Preliminary Final Report

28-Feb-2013	Half Yearly Report and Accounts

5-Feb-2013	Section 708A (5) (e) Notice

5-Feb-2013	Appendix 3B

10-Dec-2012	Notice Under S708A(5)(e)

10-Dec-2012	Appendix 3B

29-Nov-2012	Response to ASX Diversity Policy

20-Nov-2012	AGM Results

20-Nov-2012	AGM Presentation

19-Nov-2012	Notice under Section 708A(5)(e)

19-Nov-2012	Appendix 3B

2-Nov-2012	Investor Presentation

19-Oct-2012	CEO Interview Available on Website

28-Sep-2012	Annual Report to shareholders

24-Sep-2012	Zeiss Milestones Actualised

17-Sep-2012	Optiscan Presentation

10-Sep-2012	Appendix 3B

3-Sep-2012	Update, Capital Raise and Appendix 4E

31-Aug-2012	Trading Halt

31-Aug-2012	Trading Halt Request

22-Aug-2012	Response to Appendix 3Y Query

21-Aug-2012	Letter re Change of Director's Interest Notice

20-Aug-2012	Change in substantial holding

20-Aug-2012	Change of Director's Interest Notice

25-Jul-2012	Notice under Section 708A(5)(e)

25-Jul-2012	Appendix 3B

11-Jul-2012	Section 708A(5) Notice

11-Jul-2012	Appendix 3B

21-Jun-2012	Zeiss Neurosurgery Purchase Order

20-Jun-2012	Section 708A notice

20-Jun-2012	Appendix 3B

13-Jun-2012	Appendix 3B

6-Jun-2012	Shareholder Update June 2012

30-May-2012	Notice under Section 708A(5)(e) Corporations Act

30-May-2012	Appendix 3B

28-May-2012	Appendix 3B - Conversion on Notes

1-May-2012	Section 708A(5)(e) Notice

1-May-2012	Appendix 3B

30-Mar-2012	Notice under Section 708A (5)(e)

30-Mar-2012	App 3B re Bergen Funding Facility

30-Mar-2012	$2M Funding from Bergen Global Opportunity Fund, LP

30-Mar-2012	Appendix 3B

29-Feb-2012	Half Yearly Report and Accounts

31-Jan-2012	Appendix 3B

21-Nov-2011	Results of Meeting

21-Nov-2011	Chairman's Address to Shareholders

26-Oct-2011	Appendix 3B

25-Oct-2011	Notice of Annual General Meeting/Proxy Form

29-Sep-2011	Annual Report to shareholders

31-Aug-2011	Change in substantial holding from CIR

30-Aug-2011	Preliminary Final Report

11-Aug-2011	Becoming a substantial holder

10-Aug-2011	New US Patent for Optiscan

3-Aug-2011	Appendix 3B

27-Jul-2011	Strategic Review Process

8-Jun-2011	Appointment of Strategic Advisors

29-Apr-2011	Appendix 3B

23-Feb-2011	Half Yearly Report and Accounts

31-Dec-2010	Securities Trading Policy

22-Dec-2010	Expansion of activities with Carl Zeiss Surgical

29-Nov-2010	Results of Meeting

29-Nov-2010	Chairman's Address to Shareholders

9-Nov-2010	Notice of Annual General Meeting/Proxy Form

26-Oct-2010	Waiver from Listing Rules 10.13.3 and 10.13.5

16-Sep-2010	Annual Report to shareholders

31-Aug-2010	Preliminary Final Report

5-Aug-2010	Change of Director's Interest Notice

25-Jun-2010	Change of Director's Interest Notice

25-May-2010	Change of Director's Interest Notice

14-May-2010	Change of Director's Interest Notice

29-Apr-2010	March Quarter 2010 Update

26-Feb-2010	Half Yearly Report and Accounts

12-Feb-2010	Change of Director's Interest Notice

12-Feb-2010	Becoming a substantial holder

10-Feb-2010	Appendix 3B

29-Jan-2010	Change of Director's Interest Notice

20-Jan-2010	Initial Director's Interest Notice

20-Jan-2010	Final Director's Interest Notice

20-Jan-2010	Management Changes at Optiscan

24-Nov-2009	Results of Meeting

24-Nov-2009	AGM Address 2009 - text and slides

12-Nov-2009	Change of Director's Interest Notice x 3

12-Nov-2009	Appendix 3B

5-Nov-2009	Share Purchase Plan - Successful Completion

26-Oct-2009	Notice of AGM and Proxy

9-Oct-2009	Share Purchase Plan Documentation

9-Oct-2009	Share Purchase Plan Notice Under ASIC Class Order 09/425

7-Oct-2009	Share Purchase Plan Announcement

30-Sep-2009	World First in Endoscopy

29-Sep-2009	Response to an ASX Price Query

25-Sep-2009	Annual Report to shareholders

14-Sep-2009	Shareholder Newsletter

28-Aug-2009	Preliminary Final Report

7-Aug-2009	Optiscan Continues Collaboration With Carl Zeiss

3-Aug-2009	New Hoya Agreements

3-Jun-2009	Shareholder Update

14-May-2009	Final Director's Interest Notice

14-May-2009	Final Director's Interest Notice

14-May-2009	New Contract with Carl Zeiss

23-Mar-2009	Optiscan Terminates 2nd Generation Agreement with Hoya

27-Feb-2009	Half Yearly Report and Accounts

18-Feb-2009	Initial Director's Interest Notice

12-Feb-2009	Director Appointment

23-Jan-2009	Optiscan Announces Downsizing

1-Dec-2008	Final Director's Interest Notice

1-Dec-2008	Optiscan Scales down Board of Directors

24-Nov-2008	Keith Daniel Retires from Optiscan board

24-Nov-2008	Final Director's Interest Notice

24-Nov-2008	Results of Meeting

24-Nov-2008	AGM Address 2008

21-Nov-2008	Optiscan commences new trial in robotic surgery

24-Oct-2008	Notice of Annual General Meeting/Proxy Form

16-Oct-2008	Optiscan seeking to raise capital

30-Sep-2008	Annual Report to shareholders

29-Aug-2008	Preliminary Final Report

25-Aug-2008	Change of Director's Interest Notice

25-Aug-2008	Change of Director's Interest Notice

25-Aug-2008	Change of Director's Interest Notice

25-Aug-2008	Change of Director's Interest Notice

25-Aug-2008	Appendix 3B

12-Aug-2008	Results of Meeting

18-Jul-2008	Notice of General Meeting Despatched today to Members

2-Jul-2008	Initial Director's Interest Notice

19-Jun-2008	New directors for Optiscan

18-Jun-2008	S708A Notice re Placement

17-Jun-2008	Appendix 3B

17-Jun-2008	Optiscan Placement Raises $3M

11-Jun-2008	Optiscan expands global coverage for FIVE 1 sales

2-Jun-2008	Endomicroscopy Takes Centre Stage at DDW 2008

13-May-2008	Optiscan hosts one day seminar

30-Apr-2008	Multi Centre Trials in Europe Commence

29-Apr-2008	Successful Milan Conference for Optiscan

4-Apr-2008	Endomicroscopy Conference in Milan

20-Mar-2008	Surgeons Can Now See What to Cut Thanks to Optiscan

28-Feb-2008	Half Yearly Report and Accounts

13-Feb-2008	Initial Director's Interest Notice

12-Feb-2008	Issue of employee options

12-Feb-2008	Optiscan Appoints New CEO as Director

2-Jan-2008	Appendix 3Y G Latta

31-Dec-2007	CEO Steps Down

21-Dec-2007	App 3Y G Latta

20-Dec-2007	App 3Y A Rogers

20-Dec-2007	App 3Y G Latta

11-Dec-2007	OPTISCAN APPOINTS NEW CEO

7-Nov-2007	Results of Meeting

7-Nov-2007	AGM Address 2007

9-Oct-2007	Notice of Annual General Meeting/Proxy Form

2-Oct-2007	Optiscan initiates endometriosis clinical trial

24-Sep-2007	Annual Report to shareholders

5-Sep-2007	Pentax reaffirms commitment to endomicroscope sales growth

29-Aug-2007	Preliminary Final Report

13-Aug-2007	Optiscan CEO to step down by year end

8-Aug-2007	Hoya bid for Pentax Successful

2-Aug-2007	Soft sales for Optiscan in first half year

1-Aug-2007	Appendix 3B Issue of employee options

1-Aug-2007	Appendix 3B

16-Jul-2007	Pentax UK announces new training centre for

10-Jul-2007	Optiscan July 2007 investor presentation on website

10-Jul-2007	Optiscan product sales 2006/07 $5.49M

10-Jul-2007	Successful pilot trial indicates airways applications

3-Jul-2007	Optiscan and Carl Zeiss Group Sign Collaboration Deal

25-Jun-2007	New Endomicroscope Trial at Johns Hopkins Hospital

21-Jun-2007	New Pentax Development Agreement for Optiscan

20-Jun-2007	Appendix 3B: Exercise of Employee Options

20-Jun-2007	Optiscans endomicroscopy features in UK awards

12-Jun-2007	Pentax & Hoya Merger Update

30-May-2007	Change in substantial holding - Ixohoxi

25-May-2007	Endo-microscopy featured in State of the Art Lecture at DDW

22-May-2007	Expanding role for endo-microscopy reported at DDW congress

2-May-2007	Optiscan in US Roadshow

18-Apr-2007	Award for Optiscan Founders

18-Apr-2007	Change in substantial holding from CIR

17-Apr-2007	Appendix 3B

17-Apr-2007	Completion of Share Purchase Plan

28-Mar-2007	Optiscan FIVE 1 progress confirms second commercialisation

26-Mar-2007	Share Purchase Plan Extension of Closing Date

26-Mar-2007	Congress presentations for Optiscans Endo-microscopy

13-Mar-2007	Letter to Shareholders re Share Purchase Plan

28-Feb-2007	Endo-microscopy training expanded

21-Feb-2007	Share purchase plan to strengthen balance sheet

21-Feb-2007	Half Yearly Report & Accounts

24-Jan-2007	First half product sales and outlook for year

11-Jan-2007	Pentax & Hoya merger signals growth for endoscope business